Tango Therapeutics surged 53% after early pancreatic cancer study data showed strong response rates for vopimetostat combinations. The results support the company’s late-stage development plans and suggest meaningful clinical upside. The move appears driven by encouraging proof-of-concept data in a high-need oncology indication.
Tango Therapeutics surged 53% after early pancreatic cancer study data showed strong response rates for vopimetostat combinations. The results support the company’s late-stage development plans and suggest meaningful clinical upside. The move appears driven by encouraging proof-of-concept data in a high-need oncology indication.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.78
Ticker Sentiment
